With the CDK4/6 inhibitor palbociclib approved for the treatment of breast cancer and inhibitors of other CDKs that exhibit antiproliferative effects at various stages of preclinical and clinical testing, therapeutic interest in this family of serine‐threonine kinases is growing.1, 2. This evidence concerns the gene CDK4 and breast carcinoma.